Serra M, Scotlandi K, Manara M C, Maurici D, Benini S, Sarti M, Campanacci M, Baldini N
Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy.
Eur J Cancer. 1995 Nov;31A(12):1998-2002. doi: 10.1016/0959-8049(95)00335-5.
Current treatment of high-grade osteosarcoma combines surgical removal of the lesion with chemotherapy. In this study we evaluated whether the expression of P-glycoprotein, a protein closely associated with multidrug resistance, may be helpful in identifying the patients whose tumours will be further resistant to specific agents. By using multidrug-resistant osteosarcoma cell lines as standards, the expression of P-glycoprotein was evaluated in 105 cases of primary and metastatic osteosarcoma by semiquantitative immunofluorescence. Overexpression of the protein was shown in 23% of primary and in 50% of metastatic lesions. In 38 cases, homogeneously treated and followed-up for at least 24 months, overexpression of P-glycoprotein appeared to be associated with a higher relapse rate and with a trend toward a worse outcome. These data support the role of P-glycoprotein in the response to chemotherapy and its involvement in the determination of the outcome of osteosarcoma patients.
目前,高级别骨肉瘤的治疗方法是将手术切除病灶与化疗相结合。在本研究中,我们评估了与多药耐药密切相关的P-糖蛋白的表达是否有助于识别其肿瘤对特定药物将产生进一步耐药性的患者。以多药耐药骨肉瘤细胞系为标准,通过半定量免疫荧光法评估了105例原发性和转移性骨肉瘤中P-糖蛋白的表达。该蛋白在23%的原发性病灶和50%的转移性病灶中呈过表达。在38例接受统一治疗并随访至少24个月的病例中,P-糖蛋白过表达似乎与较高的复发率以及预后较差的趋势相关。这些数据支持了P-糖蛋白在化疗反应中的作用及其在骨肉瘤患者预后判定中的作用。